Epidemiologie des Hochdruckherzens

M. Middeke

doi:10.1055/s-0028-1100956

DMW - Deutsche Medizinische Wochenschrift, Inhaltsverzeichnis

Dtsch Med Wochenschr 2008; 133: S253-S256
DOI: 10.1055/s-0028-1100956

Übersicht | Review article

Kardiologie, Hypertensiologie
© Georg Thieme Verlag KG Stuttgart · New York

Epidemiologie des Hochdruckherzens

Epidemiology of the hypertensive heartM. Middeke¹

¹Hypertoniezentrum München

Abstract

Schlüsselwörter

Hochdruckherz - Linksventrikuläre Hypertrophie

Keywords

hypertensive heart disease - left ventricular hypertrophy

Volltext

Referenzen

Literatur

1 Beckett N S, Peters R, Fletcher A E. et al, for the HYVET Study Group . Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med. 2008; 358 1887-98
2 Casale P N, Devereux R B, Milner M. et al . Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986; 105 173-178
3 Coca A, Gabriel R, de la Figuera M. et al . The impact of different echocardiographic diagnostic criteria on the prevalence of the left ventricular hypertrophy in essential hypertension: the VITAE study. J Hypertens. 1999; 17 1471-1480
4 Dahlöf B, Devereux R B, Kjeldsen S E. et al . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359 995-1003
5 Devereux R B, Casale P N, Kligfield P. et al . Performance of primary and derived M-mode echocardiographic measurements for detection of left ventricular hypertrophy in necropsied subjects and in patients with systemic hypertension, mitral regurgitation and dilated cardiomyopathy. Am J Cardiol. 1986; 57 (15) 1388-93
6 Franz I W, Tönnesmann U, Müller J F. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens. 1998; 1 631-9
7 Gottdiener J S, Brown J, Zoltick J, Fletcher R D. Left ventricular hypertrophy in men with normal blood pressure: relation to exaggerated blood pressure response to exercise. Ann Intern Med. 1990; 112 (3) 161-66
8 Guidelines: 2007 Guidelines for the Management of Arterial Hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25 1105-1187
9 Hammond I W, Devereux R B, Alderman M H. et al . The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol. 1986; 7 639-650
10 Ikeda. et al . Morning rise in blood pressure associates with hypertensive cardiovascular complications. J Hypertens. 2002; 20 (Suppl 4) S150
11 Jung J. Vorhofflimmern als Endpunkt bei Studien zur arteriellen Hypertonie. Dtsch Med Wochenschr. 2003; 129 2493-46
12 Kannel W B, Gordon T, Offutt T. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med. 1969; 71 (1) 89-105
13 Kannel W B. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J. 1992; 13 (Suppl D) 82-88
14 Klingbeil A U, Schneider M, Martus P, Messerli F H, Schmieder R E. et al . A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med. 2003; 115 41
15 Lauer M S, Levy D, Anderson K M, Plehn J F. Is there a relationship between exercise systolic blood pressure response and left ventricular mass? The Framingham Heart Study. Ann Intern Med. 1992; 116 (3) 203-10
16 Levy D, Anderson K M, Savage D D. et al . Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. Ann Intern Med. 1988; 108 7-13
17 Levy D. Clinical significance of left ventricular hypertrophy: insights from the Framingham Study. J Cardiovasc Pharmcol. 1991; 17 Suppl 2 S1-6
18 Lindholm L H, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005; 366 (9496) 1545-53
19 Lopez A D, Mathers C D, Ezzati M. et al . Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006; 367 1747-57
20 MacMahon S, Peto R, Cutler J. et al . Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990; 335 765-74
21 Mancia G, Zanchetti A, Agabiti-Rosei E. et al . Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997; 95 1464-1470
22 Matsuo. et al . Morning rise in blood pressure is a risk factor for cardiovascular complications in treated hypertensive patients. J Hypertens. 2002; 20 (Suppl 4) S314
23 Meisinger C, Heier M, Völzke H. Regional disparities of hypertension prevalence and management within Germanyet al. Journal of Hypertension. 2006; 24 293-299
24 Middeke M. Hypertensiologie 2007. Dtsch Med Wochenschr. 2007; 132 1368-72
25 Middeke M. Praxismormotonie. In: Middeke Arterielle Hypertonie. Stuttgart New York; Georg Thieme Verlag 2005
26 Mosterd A, D’Agostino R B, Silbershatz H. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 – 1989. N Engl J Med. 1999; 340 1221-27
27 Motz W, Vogt M, Rabenau O, Scheler S, Lückhoff A, Strauer B E. Evidence of endothelial dysfunction in coronary resistance vessels in patients with angina pectoris and normal coronary angiograms. Am J Cardiol. 1991; 68 (10) 996-03
28 Motz W, Scheler S, Strauer B E. Coronary microangiopathy in hypertensive heart disease: pathogenesis, diagnosis and therapy. Herz. 1995; 33 901-09
29 Muiesan M L, Salvetti M, Rizzoni D. et al . Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995; 13 1091-1095
30 Norman J E. Improved detection of echocrdiographic left ventricular hypertrophy using a new electrocardiographic algorithm. J Am Coll Cardiol. 1993; 21 1680-86
31 Ott C, Schwarz T, Hilgers K F. et al . Left-ventricular structure and function are influenced by angiotensinogen gene polymorphism (-20 A/C) in young male patients. Am J Hypertens. 2007; 20 (9) 974-80
32 Ott C, Titze S I, Schwarz T K. et al . High sodium intake modulates left ventricular mass in patients with G expression of + 1675 G/A angiotensin II receptor type 2 gene. J Hypertens. 2007; 25 (8) 1627-32
33 Plehn G, Schwartzkopff B. Gestörte Dehnbarkeit des Hochdruckherzens unter Belastung als früher Marker einer diastolischen Dysfunktion. Dtsch Med Wochenschr. 2005; 130 568-73
34 Savage D D, Drayer J I, Henry W L. et al . Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation. 1979; 59 623-632
35 Schillaci G, Verdecchia P, Porcellati C. et al . Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. ypertension. 2000; 35 580-586
36 Schirmer H, Lunde P, Rasmussen K. Prevalence of left ventricular hypertrophy in general population; The Tromso Study. Eur Heart J. 1999; 20 429-38
37 Schmieder R E, Langenfeld M R, Friedrich A. et al . Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation. 1996; 94 1304-1309
38 Schwartzkopff B, Motz W, Frenzel H, Vogt M, Knauer S, Strauer B E. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation. 1993; 88 993-03
39 Sokolow M, Lyon T P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949; 37 (2) 161-86
40 Strauer B E. Das Hochdruckherz. Pathophysiologie-Diagnostik-Therapie. Berlin; Springer-Verlag 1983: 1-184
41 Strauer B E. Ventricular function and coronary hemodynamics in hypertensive heart disease. Am J Cardiol. 1979; 44 999-06
42 UK Prospective Diabetes Study Group . Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 39. BMJ. 1998; 317 713-20 und 703 – 13
43 Vakili B A, Okin P M, Devereux R B. Prognostic implications of left ventricular hypertrophy. Am Heart J. 2001; 141 334-341
44 Vaudo G, Schillaci G, Evangelista F. et al . Arterial wall thickening at different sites and its association with left ventricular hypertrophy in newly diagnosed essential hypertension. Am J Hypertens. 2000; 13 324-31
45 Verdecchia P, Schillaci G, Borgioni C. et al . Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation. 1998; 97 48-54
46 Verdecchia P, Reboldi G, Gattobigio R. et al . Atrial fibrillation in hypertension: predictors and outcome. ypertension. 2003; 41 218-223
47 Walenta K, Böhm M. Hypertensive Koronaropathie. Dtsch Med Wochenschr. 2003; 129 2476-78

Prof. Dr. med. Martin Middeke

Hypertoniezentrum München

Dienerstr. 12

80331 München

eMail: info@blutdruckinstitut.de

URL: http://www.hypertoniezentrum.de